NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 2026-11-03 15:09இன்று 117 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Sudeep Pharma Reports Record Q2 Revenue of ₹196 Cr, Up 21% YoY; EBITDA Margin Expands to 37.2%
Sudeep Pharma Limited released its Q2 FY27 earnings call transcript, highlighting record quarterly revenue of ₹196 crore (up 21% YoY and 24% QoQ) and EBITDA of ₹73 crore (up 32% YoY). Growth was primarily driven by the Pharma Food Nutrition (PFN) division, which surged 57% YoY to ₹142 crore with a 41% EBITDA margin. The company faced elevated sea freight costs of approximately ₹8 crore above normal levels and temporary pauses in the Government of India's Fortified Rice program impacting Specialty Ingredients. Management indicated its 51,000 MT greenfield Nandesari facility received FDA approval with commercial supplies starting in H2 FY27, while its 25,000 MT battery material facility is slated for validation by early FY28.
உச்சம் நம்பிக்கை
என்ன மாறியதுFiling of the formal Q2 & H1 FY27 earnings conference call transcript following the financial results.
ஏன் இது முக்கியம்Provides detailed operational insights, segment margin breakdowns, and visibility on the ramp-up of new greenfield capacity as well as battery material entry.
📅 குறுகிய காலம்Performance is underpinned by strong PFN momentum, though elevated freight expenses and startup costs from new capacity may cap incremental margin expansion in the near term.
📈 நீண்ட காலம்Structural growth relies on scaling the newly approved 51,000 MT Nandesari plant and entering the global LFP battery material supply chain with its upcoming 25,000 MT facility.
⚠ அபாய எச்சரிக்கைகள்
Continued pause in Government of India Fortified Rice procurement impacting Specialty Ingredients
Elevated international freight and logistics expenses
Customer qualification and validation delays for new greenfield and battery material capacities
👀 கவனிக்க வேண்டியவை
Track the commercial qualification timeline of the 51,000 MT Nandesari facility in H2 FY27 and binding contract announcements for the 25,000 MT battery materials facility planned for export to Korea and the US.
Q2 FY27 Revenue Rises 21% YoY to Rs 196.7 Cr; EBITDA Up 32% to Rs 73.2 Cr
Sudeep Pharma reported its highest-ever quarterly operational performance in Q2 FY27, with consolidated revenue rising 21% YoY to Rs 196.7 crore. EBITDA grew 32% YoY to Rs 73.2 crore, expanding margins by ~70 bps YoY to 37.2%, while PAT grew 11% YoY to Rs 51.8 crore. Operational milestones include receipt of US FDA approval for the 51,200 MT Nandesari facility (commercial supplies expected in H2 FY27). Furthermore, its Rs 300 crore Phase 1 Dahej battery-grade iron phosphate capex (25,000 MTPA) is on schedule for completion by March 2027.
உச்சம் நம்பிக்கை
என்ன மாறியதுSudeep Pharma published its Q2 FY27 investor presentation following strong operational performance and FDA approval for its Nandesari greenfield facility.
ஏன் இது முக்கியம்The company continues to expand operating margins (37.2%) while entering regulated markets with new FDA clearance and executing a major diversification into EV battery materials.
📅 குறுகிய காலம்Earnings sentiment is supported by record quarterly revenues and strong 37.2% EBITDA margins alongside the earnings call scheduled for October 29, 2026.
📈 நீண்ட காலம்Securing FDA approvals for 51,200 MT capacity and diversifying into 25,000 MTPA battery-grade iron phosphate creates scalable multi-year revenue drivers beyond existing nutrition excipients.
⚠ அபாய எச்சரிக்கைகள்
Execution and off-take risks on the Rs 300 crore Dahej battery project
Elevated logistics costs and global tariff uncertainties
Customer concentration with top 10 customers accounting for ~42% of revenue
👀 கவனிக்க வேண்டியவை
Track the commercial ramp-up of the FDA-approved Nandesari facility in H2 FY27 and commissioning progress on the Rs 300 crore Dahej battery materials facility targeted for March 2027.
Sudeep Pharma Q2 FY27 Consolidated PAT Up 10.8% YoY to ₹51.81 Cr; Revenue Rises 20.9%
Sudeep Pharma Limited reported its Q2 FY27 (quarter ended September 30, 2026) consolidated results, posting a 20.9% YoY increase in revenue from operations to ₹196.70 crore compared to ₹162.67 crore in Q2 FY26. Consolidated profit after tax grew 10.8% YoY to ₹51.81 crore from ₹46.78 crore in the corresponding quarter last year. Profit before tax rose 19.3% YoY to ₹71.03 crore, while basic EPS stood at ₹4.59 versus ₹4.20 a year ago. For H1 FY27, total revenue reached ₹354.97 crore with a net profit of ₹92.40 crore.
உச்சம் நம்பிக்கை
என்ன மாறியதுSudeep Pharma published its unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026.
ஏன் இது முக்கியம்Demonstrates consistent ~21% topline growth and healthy net margins in pharmaceutical, food, and nutrition segments, supporting its targeted multi-year growth trajectory.
📅 குறுகிய காலம்Stable operational performance with revenue and profit growth should provide supportive sentiment around upcoming quarters.
📈 நீண்ட காலம்Sustained revenue growth aligns with broader capacity expansions and international integration (NSS Ireland and Dahej facility).
⚠ அபாய எச்சரிக்கைகள்
Raw material cost variations and potential pass-through lag
Customer concentration with top 10 clients accounting for over 40% of sales
👀 கவனிக்க வேண்டியவை
Track the deployment of unutilized IPO proceeds (₹55.81 crore) toward machinery capex at the Nandesari facility, and monitor upcoming commentary on battery materials expansion.
FDA Approves 51,200 MT Greenfield Facility at Nandesari, Gujarat for Sudeep Pharma
Sudeep Pharma has received regulatory approval from the Gujarat FDA to commence operations at its new greenfield facility at 179 Nandesari, Gujarat. The facility adds an installed annual capacity of 51,200 MT, which represents a ~71% increase over its existing 72,246 MT capacity. Commercial supplies are slated to commence in H2 FY27 after customer qualifications, with 60% capacity allocated to existing pharma/nutrition products and 40% to newer high-value molecules like bisglycinates.
உச்சம் நம்பிக்கை
என்ன மாறியதுGujarat FDA granted regulatory approval to begin manufacturing operations at Sudeep Pharma's 179 Nandesari greenfield facility.
ஏன் இது முக்கியம்The approval unlocks a ~71% expansion in total manufacturing volume, directly relieving capacity constraints on high-value molecules like bisglycinates to drive top-line growth.
📅 குறுகிய காலம்Positive sentiment from clearing a major regulatory hurdle, though revenue impact will be deferred until commercial shipments start in H2 FY27.
📈 நீண்ட காலம்Significantly enhances long-term production capability by ~71%, unlocking supply constraints in higher-margin specialized ingredients and regulated markets.
⚠ அபாய எச்சரிக்கைகள்
Revenue realization lag until H2 FY27 pending customer audits and qualifications
Execution and ramp-up risks typical of greenfield chemical/pharma sites
👀 கவனிக்க வேண்டியவை
Track customer qualification and audit milestones ahead of the planned commercial ramp-up in H2 FY27, along with gross margin progression as higher-value bisglycinates come online.
27% Revenue Growth in Q1 FY27; Specialty Ingredient Sales Surpass Full Year FY26 Levels
Sudeep Pharma reported a strong 27% YoY consolidated revenue growth for Q1 FY27, driven by a 31% surge in the Pharma, Food, and Nutrition segment. A standout performance was seen in the Absorbis Bisglycinates portfolio, where Q1 sales alone exceeded the total sales achieved in the entire previous financial year. Despite a 50% spike in phosphoric acid costs, management is maintaining an EBITDA margin target of 37-38% through price pass-throughs. The company is also progressing on its battery materials facility (25,000 MT) with a strict non-China supply chain strategy to ensure US market compliance.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has successfully transitioned its specialty ingredient portfolio to a high-growth phase and is shifting from a distributor-led to a direct-to-customer model in Europe.
ஏன் இது முக்கியம்The massive growth in specialty ingredients (Absorbis) indicates a successful move up the value chain, while the battery materials strategy provides a long-term structural growth lever independent of traditional pharma cycles.
Revenue Growth (YoY): 27%Pharma/Nutrition Segment Growth: 31%Phosphoric Acid Price Hike: 50%Target EBITDA Margin: 37-38%Total Planned Capacity: 123,446 MTLong-term Working Capital Target: 150 நாட்கள்
📅 குறுகிய காலம்The stock may react positively to the significant outperformance in the specialty segment and the management's confidence in maintaining high margins despite cost pressures.
📈 நீண்ட காலம்The expansion into battery materials (targeting 100-200 KTPA eventually) and the doubling of core capacity position the company for a significant scale-up over the next 2-3 years.
⚠ அபாய எச்சரிக்கைகள்
Raw material price volatility (Phosphoric Acid)
Geopolitical logistics disruptions affecting European subsidiaries
Execution risk in the new battery materials segment
👀 கவனிக்க வேண்டியவை
Watch for the margin trajectory in Q2 FY27 to confirm the successful pass-through of raw material costs and monitor the execution timeline of the Dahej facility which nearly doubles existing capacity.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
27% Revenue Growth in Q1FY27; Rs 300 Cr Battery Material Project on Track for March 2027
Sudeep Pharma reported a strong Q1FY27 with revenue growing 27% YoY to Rs 158.3 cr and PAT increasing 30% to Rs 40.6 cr. The company is aggressively diversifying into the EV battery materials segment (SAM project) with a Rs 300 cr investment, targeting 25,000 MT capacity by March 2027. Despite headwinds in the European market (NSS subsidiary) and elevated logistics costs, EBITDA margins remained resilient at 34.7%. The company also signed two additional MoUs with South Korean manufacturers for battery-grade iron phosphate.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has transitioned from reporting historical performance to providing concrete timelines and MoU progress for its major diversification into EV battery materials.
ஏன் இது முக்கியம்The entry into battery-grade iron phosphate (25,000 MT) represents a significant high-growth pivot from traditional pharma excipients, with the project cost representing nearly 47% of FY26 revenue.
📅 குறுகிய காலம்The strong Q1 earnings and progress on the battery material MoUs are likely to support positive sentiment in the coming weeks.
📈 நீண்ட காலம்The structural shift towards becoming a non-Chinese supplier for the EV battery supply chain, combined with a 70% increase in core capacity, provides a multi-year growth runway.
⚠ அபாய எச்சரிக்கைகள்
Subdued demand in European markets (NSS)
Execution risk for the Rs 300 cr greenfield battery project
Exposure to global logistics and gas supply constraints
👀 கவனிக்க வேண்டியவை
Monitor the execution timeline of the SAM battery materials project scheduled for March 2027 and the conversion of MoUs into firm off-take contracts. Watch for demand recovery in the European market which currently remains subdued due to high energy costs.
29.8% YoY PAT Growth in Q1 FY27; Revenue Reaches ₹158.27 Cr
Sudeep Pharma reported a consolidated revenue of ₹158.27 cr for Q1 FY27, marking a 26.7% increase over Q1 FY26. Net profit grew 29.8% YoY to ₹40.59 cr, although it declined 16.4% sequentially from Q4 FY26. The company maintains a significant cash buffer with ₹75.46 cr of unutilized IPO proceeds currently held in bank deposits, intended for machinery procurement. Operational performance remains steady with an EPS of ₹3.59, up from ₹2.84 in the year-ago period.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has reported its Q1 FY27 financial results, showing strong year-on-year growth in both top-line and bottom-line figures, while maintaining a large unspent IPO capital pool.
ஏன் இது முக்கியம்The results validate the company's 26% expected growth trajectory and its ability to maintain profitability despite a sequential dip in revenue. The high level of unutilized IPO funds suggests a lag in capex execution which needs to be monitored.
📅 குறுகிய காலம்The stock may see positive sentiment due to strong YoY growth, though the sequential (QoQ) decline in revenue and profit might lead to some consolidation.
📈 நீண்ட காலம்The long-term outlook depends on the successful integration of the NSS acquisition and the operationalization of the 25,000 MT battery materials facility and the 51,200 MT Dahej expansion.
⚠ அபாய எச்சரிக்கைகள்
Slow utilization of IPO proceeds for planned machinery procurement
High client concentration with top 10 customers contributing 42% of revenue
Sequential decline in revenue and profit compared to Q4 FY26
👀 கவனிக்க வேண்டியவை
Investors should monitor the deployment timeline of the ₹75.46 cr unutilized IPO proceeds into machinery, which is critical for capacity ramp-up. Additionally, track the progress of the Dahej greenfield expansion and battery materials facility, which are expected to drive long-term growth by FY27.
₹642.3 Cr Revenue in FY26; 25,000 MT Battery Material Plant on Track for 2027
Sudeep Pharma reported a strong FY 2025-26 with revenue of ₹642.3 crore and a PAT margin of 27.1%. The core Pharma and Nutrition segment grew 10% to ₹362 crore, though growth was limited by near-optimal capacity utilization. A major strategic shift is underway with a 25,000 MT battery material facility in Dahej targeted for April 2027, which has already secured 700 MT in initial orders. Shareholders ratified the 2025 ESOP scheme and approved the dividend for the fiscal year.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has formalized its entry into the battery materials segment with a clear commissioning date and initial orders, while confirming strong FY26 financial performance.
ஏன் இது முக்கியம்The diversification into the EV battery ecosystem (25,000 MT capacity) provides a high-growth vertical that complements the stable but capacity-constrained pharma excipients business.
📅 குறுகிய காலம்The stock may see positive sentiment following the confirmation of strong margins and concrete progress on the new battery materials segment.
📈 நீண்ட காலம்The successful ramp-up of the 25,000 MT battery material plant and the 51,200 MT Greenfield expansion could significantly scale the business by FY28.
⚠ அபாய எச்சரிக்கைகள்
Execution risk for the Greenfield Dahej facility
Current capacity constraints in core segments
Elevated working capital due to international inventory stocking
👀 கவனிக்க வேண்டியவை
Investors should monitor the execution timeline of the Dahej battery material facility (April 2027) and the customer qualification progress at the new Nandesari facility to address current capacity constraints.
₹1.50 Final Dividend: Sudeep Pharma Sets July 23, 2026, as Record Date
Sudeep Pharma Limited has fixed July 23, 2026, as the record date for its final dividend of ₹1.50 per equity share for the financial year 2025-26. This dividend is based on a face value of ₹1 per share, representing a 150% payout. The distribution is subject to shareholder approval at the 37th Annual General Meeting (AGM) scheduled for August 4, 2026. At the current market price of ₹828.9, the dividend yield stands at approximately 0.18%.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has officially set the timeline (record date and AGM date) for the payment of its previously recommended final dividend for FY 2025-26.
ஏன் இது முக்கியம்While the dividend yield is relatively low at 0.18%, the announcement confirms the company's intent to share profits with investors following a strong Sep 2025 quarter where it reported a net profit of ₹46.78 cr.
📅 குறுகிய காலம்The stock may experience minor price adjustments around the ex-dividend date, though the low yield suggests the impact will be minimal.
📈 நீண்ட காலம்Limited. This is a routine corporate action; the long-term value remains tied to the company's 51,200 MT Greenfield expansion in Dahej and its entry into the battery materials segment.
👀 கவனிக்க வேண்டியவை
Investors interested in the dividend must hold the shares in their demat account by the record date of July 23, 2026. Monitor the AGM outcome on August 4, 2026, for formal approval of the payout.
₹1.50 Dividend and FY26 Revenue of ₹338.5 Cr Announced in 37th AGM Notice
Sudeep Pharma has issued its 37th AGM notice for August 4, 2026, proposing a dividend of ₹1.50 per share (150% payout). The company reported FY 2025-26 revenue of ₹338.51 cr, a 5.1% decline from the previous year, though Profit After Tax (PAT) grew 12.3% to ₹107.58 cr. Key agenda items include the re-appointment of Whole Time Director Mr. Ajay Kandelkar with a revised remuneration of ₹114.97 lakhs. Investors should note the high PAT margin of 31.8% despite the slight revenue contraction.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has formalized its FY26 financial performance and dividend proposal, while seeking shareholder approval for management continuity and remuneration.
ஏன் இது முக்கியம்The filing confirms the company's ability to grow profits despite a slight revenue dip, maintaining high margins in the specialized mineral-based excipients market.
📅 குறுகிய காலம்The stock may see neutral to slightly positive movement leading up to the July 28, 2026 cut-off date for dividend eligibility.
📈 நீண்ட காலம்Structural growth depends on the successful integration of the NSS (Ireland) acquisition and the commissioning of the 25,000 MT battery material facility in Dahej.
⚠ அபாய எச்சரிக்கைகள்
Client concentration (top 10 customers contribute 42% of revenue)
Raw material price volatility affecting annual contracts
👀 கவனிக்க வேண்டியவை
Monitor the approval of the dividend and the progress of the Greenfield expansion in Dahej, which is expected to add 51,200 MT of capacity and drive future revenue growth.
Sudeep Pharma Appoints CA Milin Mehta as Non-Executive Non-Independent Director
Sudeep Pharma Limited has appointed Mr. Milin Mehta as an Additional Director in the Non-Executive Non-Independent category effective June 26, 2026. Mr. Mehta is a seasoned professional with over 30 years of experience as a Chartered Accountant and Law Graduate, currently serving as the Managing Partner at K C Mehta & Co LLP. His expertise spans international tax, transfer pricing, and transaction advisory services, which is expected to strengthen the board's strategic and regulatory oversight. The appointment is subject to shareholder approval and follows a board meeting held on the same day.
முக்கிய அம்சங்கள்
Appointment of Mr. Milin Mehta as Additional Director effective June 26, 2026Mr. Mehta brings over 30 years of experience in accounting, law, and strategic leadershipHe has previously contributed to national policy initiatives including Income Computation and Disclosure Standards (ICDS)The board meeting concluded within 35 minutes, starting at 03:30 p.m. and ending at 04:05 p.m.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive step towards strengthening corporate governance and strategic advisory. No immediate action is required as this is a routine board-level appointment of a highly qualified professional.
Sudeep Pharma FY26 Revenue Growth Driven by 62% Surge in Specialty Ingredients
Sudeep Pharma reported a transformational FY26, with its specialty ingredients vertical growing 62% to INR 280 crores, now accounting for 44% of total revenue. The company successfully integrated its Irish acquisition (NSS) and is diversifying into the battery materials sector with a 25,000 MTPA project in Dahej scheduled for April 2027. Despite global raw material inflation, the company maintained margins through effective price pass-throughs and secured 51 new customer approvals during the year.
முக்கிய அம்சங்கள்
Specialty ingredients revenue grew 62% YoY from INR 172 Cr to INR 280 CrSecured 51 new customer approvals in FY26 across global marketsBattery materials project (SAM) on track for Phase 1 commissioning of 25,000 MTPA by April 2027Engaging with 42 global customers for battery-grade iron phosphate, with 6 already completing commercial validationPharma food and nutrition vertical grew 10% despite phosphoric acid price volatility
👀 கவனிக்க வேண்டியவை
Investors should monitor the commissioning of the Dahej battery materials plant and the ramp-up of the new greenfield facility as primary growth catalysts. The strategic shift toward high-margin specialty ingredients and the 'China Plus One' opportunity in battery materials provide a strong long-term outlook.
Sudeep Pharma FY26 Revenue Jumps 28% to ₹642.3 Cr; Battery Materials Plant Construction Underway
Sudeep Pharma reported a robust performance for FY26, with revenue growing 28% YoY to ₹642.3 crore and PAT rising 26% to ₹174.3 crore. The year was marked by the successful integration of Nutrition Supplies Services (NSS) and the groundbreaking of a new battery materials facility in Dahej. While EBITDA margins compressed slightly to 34.6% due to rising raw material costs and gas supply issues, the company secured significant initial orders for its battery-grade iron phosphate. Working capital days increased to 213, primarily due to strategic inventory buildup and geopolitical supply chain disruptions.
முக்கிய அம்சங்கள்
Annual revenue reached a record ₹642.3 crore in FY26, driven by a 28% YoY growth and NSS integration.Groundbreaking completed for the Dahej Battery Materials Plant with an initial Phase 1 capacity of 25,000 MT.Secured a 500 MT purchase order for battery materials from a leading listed Indian player and qualification orders from Korea.Acquired an 85% stake in Nutrition Supplies Services (NSS), significantly expanding European market reach.Working capital cycle lengthened to 213 days from 184 days YoY due to US/Europe warehousing and West Asia conflict disruptions.
👀 கவனிக்க வேண்டியவை
Investors should focus on the execution of the Dahej greenfield project and the company's transition into the EV supply chain. While working capital is currently stretched, the strong growth in the core pharma/nutrition business and high ROCE of 22.5% provide a solid foundation.
Sudeep Pharma Recommends Final Dividend of Rs 1.50 (150%) for FY 2025-26
Sudeep Pharma Limited's Board of Directors has recommended a final dividend of Rs. 1.50 per equity share, representing a 150% payout on the face value of Rs. 1. This recommendation follows the approval of the company's audited standalone and consolidated financial results for the fiscal year ended March 31, 2026. The company also announced the appointment of new Cost and Secretarial auditors for the upcoming periods. The dividend remains subject to shareholder approval at the forthcoming Annual General Meeting.
முக்கிய அம்சங்கள்
Recommended a final dividend of Rs. 1.50 per equity share (150% of face value) for FY 2025-26.Approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.Appointed M/s H M Mehta & Associates as Secretarial Auditor for a five-year term until FY 2030-31.Appointed M/s Chetan Gandhi & Associates as Cost Auditor for the financial year 2026-27.Statutory auditors B S R and Co issued an unmodified audit report on the consolidated financial results.
👀 கவனிக்க வேண்டியவை
Investors should track the upcoming Annual General Meeting (AGM) and the subsequent record date to qualify for the Rs. 1.50 dividend. The 150% dividend payout suggests a stable financial position and a shareholder-friendly management approach.
Sudeep Pharma Q3 FY26 Earnings Call: 20% Domestic Growth and Major Capacity Expansion
Sudeep Pharma reported a steady Q3 FY26 performance with 20% growth in the domestic market and strong traction in APAC and Europe. The company is strategically pivoting towards high-margin specialty ingredients and battery-grade iron phosphate, positioning itself as a key ex-China supplier. Significant capacity expansions are underway, including the 51,200 MTPA Nandesari facility due in March 2026 and the 25,000 MTPA Dahej battery materials plant slated for 2027. Management highlighted deepening relationships with global FMCG and baked goods leaders, providing long-term revenue visibility.
முக்கிய அம்சங்கள்
Domestic market revenue grew by nearly 20% in Q3 FY26 supported by stable demand.Nandesari Greenfield facility with 51,200 MTPA capacity is on track for commissioning in March 2026.Phase 1 of the Dahej Battery Materials facility (25,000 MTPA) is scheduled for commissioning in early 2027.Currently engaged with 34 global customers for battery-grade iron phosphate, with a 70% sample approval rate.Upgraded existing facilities to add 5,000 tons of battery-grade iron phosphate capacity to serve commercial scale-up orders.
👀 கவனிக்க வேண்டியவை
Investors should monitor the timely commissioning of the Nandesari facility in March 2026 as it will drive the next phase of volume growth. The company's unique position as an ex-China supplier for battery materials makes it a high-potential play in the EV supply chain.
Sudeep Pharma Q3 FY26 PAT Surges 66% YoY; Groundbreaking for 25,000 MT Battery Chemicals Plant
Sudeep Pharma reported a robust Q3 FY26 with total income rising 52% YoY to ₹179.2 crore, driven by strong demand in specialty ingredients and pharma segments. Profit After Tax (PAT) surged 66% YoY to ₹47.7 crore, supported by healthy EBITDA margins of 37.3%. A major strategic highlight is the company's entry into the EV battery materials space with a new 25,000 MT plant in Dahej and the commencement of early commercial orders. The company is also on track to commission its Nandesari greenfield facility by Q4 FY26, further boosting capacity.
முக்கிய அம்சங்கள்
Total Income grew 52% YoY to ₹179.2 Cr in Q3 FY26; 9M FY26 revenue reached ₹482.1 Cr.EBITDA increased 60% YoY to ₹66.8 Cr with margins expanding to 37.3% from 35.4% YoY.Groundbreaking of Dahej Battery Chemicals Plant (Phase I: 25,000 MT) targeting the LFP battery market with a total project cost of ₹300 Cr.Successfully upgraded existing iron phosphate capacity to 5,000 MT for battery-grade materials and secured initial commercial orders.Greenfield manufacturing facility at Nandesari is on track for commissioning by Q4 FY26.
👀 கவனிக்க வேண்டியவை
Investors should note the strong earnings momentum and the significant strategic pivot into the high-growth EV battery materials sector as a long-term catalyst. Monitor the execution timelines of the Dahej plant and the ramp-up of the new Nandesari facility for sustained growth.
Sudeep Pharma Q3 FY26 Net Profit Rises 30% YoY to ₹26.87 Crore; Revenue Up 8%
Sudeep Pharma reported a strong performance for Q3 FY26, with standalone net profit growing 30.2% year-on-year to ₹26.87 crore. Revenue from operations saw a steady increase of 8.1% to ₹90.28 crore, while total income was bolstered by a significant rise in other income to ₹9.44 crore. For the nine-month period ended December 2025, the company achieved a profit of ₹81.82 crore, a 30.7% increase compared to the previous year. The company, which listed in November 2025, still holds ₹75.81 crore of unutilized IPO proceeds in term deposits intended for future capital expenditure.
முக்கிய அம்சங்கள்
Net Profit for Q3 FY26 increased by 30.2% YoY to ₹26.87 crore from ₹20.63 crore.Revenue from operations grew 8.1% YoY to ₹90.28 crore in the December quarter.9M FY26 profit stands at ₹81.82 crore, up significantly from ₹62.61 crore in 9M FY25.Other income jumped to ₹9.44 crore in Q3 FY26 compared to ₹2.29 crore in the same quarter last year.Unutilized IPO proceeds of ₹75.81 crore are currently held in bank term deposits for planned machinery procurement.
👀 கவனிக்க வேண்டியவை
The company shows robust profit growth and efficient cost management in its first results post-listing. Investors should monitor the timely deployment of IPO proceeds into machinery, which is the primary catalyst for future capacity expansion.
Sudeep Pharma Subsidiary Acquires Land in Dahej for ₹20.97 Cr for Battery Materials Plant
Sudeep Pharma's wholly-owned subsidiary, Sudeep Advanced Materials Private Limited, has acquired leasehold land rights in GIDC Dahej, Gujarat, for ₹20.97 crore. The land, measuring approximately 80,980 square meters, was purchased from DCM Shriram Fine Chemicals Limited. This strategic acquisition is intended for setting up a commercial manufacturing facility for Battery Grade Precursor Materials, specifically Iron Phosphate. This move marks a significant expansion into the high-growth electric vehicle and energy storage supply chain.
முக்கிய அம்சங்கள்
Acquisition of 80,980.19 square meters of leasehold land in GIDC Dahej, GujaratTotal transaction value of ₹20,97,03,000 excluding transfer charges and dutiesLand purchased from DCM Shriram Fine Chemicals Limited by a wholly-owned subsidiaryNew facility to focus on manufacturing Battery Grade Precursor Materials like Iron PhosphateStrategic diversification into the renewable energy and EV battery material sector
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive long-term growth driver as the company enters the specialized battery materials market. Monitor future announcements regarding project timelines, capital expenditure for the plant, and potential off-take agreements.
Sudeep Pharma Q2 FY26: Specialty Segment Grows 32% CAGR; New Plant to Commission in Q4
Sudeep Pharma conducted its maiden earnings call post-listing, highlighting a robust 32% CAGR in its specialty ingredients vertical since 2021, which now accounts for 40% of total revenue. The company is on track to commission its fifth and largest manufacturing facility in Nandesari by Q4 FY26 to address rising demand in regulated pharma and infant nutrition markets. Management clarified that 50% of its US business is exempt from recent tariffs, with customers absorbing the remaining impact, ensuring no significant volume loss. The strategic 85% acquisition of Ireland-based NSS in May 2025 further strengthens its global footprint in the high-barrier infant and medical nutrition segments.
முக்கிய அம்சங்கள்
Specialty ingredients vertical achieved a 32% CAGR since 2021, contributing 40% of H1 FY26 revenues.Fifth greenfield manufacturing facility in Nandesari, Gujarat, expected to be commissioned in Q4 FY26.Acquired 85% stake in Ireland-based Nutrition Supplies and Services (NSS) to accelerate entry into infant nutrition.Management confirmed 50% of US business is exempt from tariffs, with the rest seeing costs absorbed by clients.Expanding into the battery materials market through Sudeep Advanced Materials (SAM) for LFP battery components.
👀 கவனிக்க வேண்டியவை
Investors should monitor the successful commissioning and ramp-up of the Nandesari facility in Q4 FY26 as a key growth driver. The stock offers unique exposure to high-barrier pharmaceutical excipients and the emerging LFP battery material supply chain.
Sudeep Pharma Q2FY26 Update: FY25 Revenue at ₹502 Cr with 39.7% EBITDA Margin
Sudeep Pharma, which listed on BSE/NSE in November 2025, reported robust FY25 financials with a PAT of ₹139 crore and a high ROE of 28.1%. The company is undergoing a major capacity expansion, adding 51,200 MT to its existing 72,246 MT capacity, with commissioning expected by Q4FY26. It maintains a strong global presence across 100 countries, serving 1,100+ customers including 14 Fortune 500 companies. Additionally, the company is diversifying into high-growth battery materials, specifically iron phosphate for LFP batteries.
முக்கிய அம்சங்கள்
FY25 Revenue of ₹502 Cr with a strong EBITDA margin of 39.7% and PAT margin of 27.6%.Total manufacturing capacity to reach 1,23,446 MT following the commissioning of a new facility in Q4FY26.High customer stickiness with 83.17% repeat business and an average 7-year relationship with top 5 customers.Diversified revenue stream with 60% from Specialty Ingredients and 40% from Pharma, Food & Nutrition in H1FY26.Strategic entry into sustainable battery materials through subsidiary Sudeep Advanced Materials (SAMPL).
👀 கவனிக்க வேண்டியவை
Investors should track the timely commissioning of the new Nandesari facility in Q4FY26, which will increase capacity by approximately 70%. The company's entry into the EV battery material supply chain provides a significant long-term growth catalyst beyond its core pharma excipients business.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
